

Global Radioligand Therapy Drugs for Cancer Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/RC10CDAFDE1CEN.html>

Date: January 2026

Pages: 118

Price: US\$ 3,480.00 (Single User License)

ID: RC10CDAFDE1CEN

Abstracts

According to our (Global Info Research) latest study, the global Radioligand Therapy Drugs for Cancer market size was valued at US\$ 3369 million in 2025 and is forecast to a readjusted size of US\$ 5581 million by 2032 with a CAGR of 7.6% during review period.

In 2025, global Radioligand Therapy Drugs for Cancer reached approximately 76.86 K Units, with an average global market price of around 42598 USD per Unit.

Radioligand Therapy (RLT) drugs are targeted radiopharmaceutical cancer medicines that pair a tumor-seeking “ligand” (targeting molecule) with a therapeutic radioactive isotope (radionuclide). After intravenous administration, the ligand binds to a specific target on (or in) cancer cells, and the radionuclide delivers cell-killing radiation locally, aiming to limit exposure to surrounding healthy tissue.

Radioligand therapy (RLT) drugs combine the precision of targeted medicine with the cell-killing power of radiation, delivering a therapeutic payload directly to tumors based on a molecular marker rather than just anatomy, which helps address several long-standing pain points in oncology: limited efficacy after multiple lines of treatment, high systemic toxicity from broadly acting drugs, and the need for better patient selection to avoid costly trial-and-error care. By pairing a targeting ligand with a therapeutic radioisotope, RLT can concentrate dose where disease is active—including small or disseminated lesions—while often remaining compatible with existing imaging workflows and multidisciplinary cancer care, making outcomes more predictable and enabling clearer treatment sequencing. Industry momentum is being driven by a convergence of factors: rapid growth in biomarker-guided oncology, rising unmet need in hard-to-treat

metastatic disease, increasing confidence from real-world clinical adoption, and meaningful investment in isotope supply, manufacturing capacity, and specialized treatment infrastructure that reduces earlier bottlenecks. Looking ahead, the market potential is reinforced by a deepening pipeline across multiple tumor types and targets, next-generation isotopes and chemistries that may improve tumor penetration and durability, and expanding global capacity that can progressively normalize availability; as these elements mature, RLT is positioned to evolve from a niche option into a more routine modality that complements—and in some settings competes with—established systemic therapies, shaping a long runway for growth without relying on hype.

Radioligand Therapy Drugs for Cancer' upstream raw materials mainly include therapeutic radionuclides, targeted ligands, and excipients. Typical suppliers include ITM, Curium, SHINE Technologies, and NRG. Downstream applications primarily involve the treatment of cancers such as prostate cancer, liver cancer, breast cancer, and lung cancer.

The production capacity of a single Radioligand Therapy Drugs for Cancer production line is affected by the supply of radionuclides, synthesis efficiency, equipment configuration, and quality control standards. Significant differences exist between different drugs and production lines. Radioligand Therapy Drugs for Cancer' gross profit margin ranges from 70% to 80%.

This report is a detailed and comprehensive analysis for global Radioligand Therapy Drugs for Cancer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Radioligand Therapy Drugs for Cancer market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Radioligand Therapy Drugs for Cancer market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Radioligand Therapy Drugs for Cancer market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2021-2032

Global Radioligand Therapy Drugs for Cancer market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2021-2026

The Primary Objectives in This Report Are:

- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Radioligand Therapy Drugs for Cancer
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace

This report profiles key players in the global Radioligand Therapy Drugs for Cancer market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Bayer, Progenics (Lantheus), Acrotech Biopharma Inc, BMS, AstraZeneca, Eli Lilly, Convergent Therapeutics, Grand Pharmaceutical, Bivision Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Radioligand Therapy Drugs for Cancer market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Lutetium 177

Radium 223

Acetium 225

Others

Market segment by Targeted Ligands

by Peptides

Small Molecules

Antibodies

Others

Market segment by Radionuclides

α -emitters

β -emitters

Others

Market segment by Application

Prostate Cancer

Liver Cancer

Breast Cancer

Lung Cancer

Others

Major players covered

Novartis

Bayer

Progenics (Lantheus)

Acrotech Biopharma Inc

BMS

AstraZeneca

Eli Lilly

Convergent Therapeutics

Grand Pharmaceutical

Bivision Pharmaceuticals

Jiangsu Hengrui

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Radioligand Therapy Drugs for Cancer product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Radioligand Therapy Drugs for Cancer,

with price, sales quantity, revenue, and global market share of Radioligand Therapy Drugs for Cancer from 2021 to 2026.

Chapter 3, the Radioligand Therapy Drugs for Cancer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Radioligand Therapy Drugs for Cancer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026. and Radioligand Therapy Drugs for Cancer market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Radioligand Therapy Drugs for Cancer.

Chapter 14 and 15, to describe Radioligand Therapy Drugs for Cancer sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Type

1.3.1 Overview: Global Radioligand Therapy Drugs for Cancer Consumption Value by Type: 2021 Versus 2025 Versus 2032

1.3.2 Lutetium

1.3.3 Radium

1.3.4 Actinium

1.3.5 Others

1.4 Market Analysis by Targeted Ligands

1.4.1 Overview: Global Radioligand Therapy Drugs for Cancer Consumption Value by Targeted Ligands: 2021 Versus 2025 Versus 2032

1.4.2 by Peptides

1.4.3 Small Molecules

1.4.4 Antibodies

1.4.5 Others

1.5 Market Analysis by Radionuclides

1.5.1 Overview: Global Radioligand Therapy Drugs for Cancer Consumption Value by Radionuclides: 2021 Versus 2025 Versus 2032

1.5.2 α -emitters

1.5.3 β -emitters

1.5.4 Others

1.6 Market Analysis by Application

1.6.1 Overview: Global Radioligand Therapy Drugs for Cancer Consumption Value by Application: 2021 Versus 2025 Versus 2032

1.6.2 Prostate Cancer

1.6.3 Liver Cancer

1.6.4 Breast Cancer

1.6.5 Lung Cancer

1.6.6 Others

1.7 Global Radioligand Therapy Drugs for Cancer Market Size & Forecast

1.7.1 Global Radioligand Therapy Drugs for Cancer Consumption Value (2021 & 2025 & 2032)

1.7.2 Global Radioligand Therapy Drugs for Cancer Sales Quantity (2021-2032)

1.7.3 Global Radioligand Therapy Drugs for Cancer Average Price (2021-2032)

2 MANUFACTURERS PROFILES

2.1 Novartis

2.1.1 Novartis Details

2.1.2 Novartis Major Business

2.1.3 Novartis Radioligand Therapy Drugs for Cancer Product and Services

2.1.4 Novartis Radioligand Therapy Drugs for Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.1.5 Novartis Recent Developments/Updates

2.2 Bayer

2.2.1 Bayer Details

2.2.2 Bayer Major Business

2.2.3 Bayer Radioligand Therapy Drugs for Cancer Product and Services

2.2.4 Bayer Radioligand Therapy Drugs for Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.2.5 Bayer Recent Developments/Updates

2.3 Progenics (Lantheus)

2.3.1 Progenics (Lantheus) Details

2.3.2 Progenics (Lantheus) Major Business

2.3.3 Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Product and Services

2.3.4 Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.3.5 Progenics (Lantheus) Recent Developments/Updates

2.4 Acrotech Biopharma Inc

2.4.1 Acrotech Biopharma Inc Details

2.4.2 Acrotech Biopharma Inc Major Business

2.4.3 Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Product and Services

2.4.4 Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.4.5 Acrotech Biopharma Inc Recent Developments/Updates

2.5 BMS

2.5.1 BMS Details

2.5.2 BMS Major Business

2.5.3 BMS Radioligand Therapy Drugs for Cancer Product and Services

2.5.4 BMS Radioligand Therapy Drugs for Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

- 2.5.5 BMS Recent Developments/Updates
- 2.6 AstraZeneca
 - 2.6.1 AstraZeneca Details
 - 2.6.2 AstraZeneca Major Business
 - 2.6.3 AstraZeneca Radioligand Therapy Drugs for Cancer Product and Services
 - 2.6.4 AstraZeneca Radioligand Therapy Drugs for Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.6.5 AstraZeneca Recent Developments/Updates
- 2.7 Eli Lilly
 - 2.7.1 Eli Lilly Details
 - 2.7.2 Eli Lilly Major Business
 - 2.7.3 Eli Lilly Radioligand Therapy Drugs for Cancer Product and Services
 - 2.7.4 Eli Lilly Radioligand Therapy Drugs for Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.7.5 Eli Lilly Recent Developments/Updates
- 2.8 Convergent Therapeutics
 - 2.8.1 Convergent Therapeutics Details
 - 2.8.2 Convergent Therapeutics Major Business
 - 2.8.3 Convergent Therapeutics Radioligand Therapy Drugs for Cancer Product and Services
 - 2.8.4 Convergent Therapeutics Radioligand Therapy Drugs for Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.8.5 Convergent Therapeutics Recent Developments/Updates
- 2.9 Grand Pharmaceutical
 - 2.9.1 Grand Pharmaceutical Details
 - 2.9.2 Grand Pharmaceutical Major Business
 - 2.9.3 Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Product and Services
 - 2.9.4 Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.9.5 Grand Pharmaceutical Recent Developments/Updates
- 2.10 Bivision Pharmaceuticals
 - 2.10.1 Bivision Pharmaceuticals Details
 - 2.10.2 Bivision Pharmaceuticals Major Business
 - 2.10.3 Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Product and Services
 - 2.10.4 Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
 - 2.10.5 Bivision Pharmaceuticals Recent Developments/Updates

2.11 Jiangsu Hengrui

2.11.1 Jiangsu Hengrui Details

2.11.2 Jiangsu Hengrui Major Business

2.11.3 Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Product and Services

2.11.4 Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.11.5 Jiangsu Hengrui Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: RADIOLIGAND THERAPY DRUGS FOR CANCER BY MANUFACTURER

3.1 Global Radioligand Therapy Drugs for Cancer Sales Quantity by Manufacturer (2021-2026)

3.2 Global Radioligand Therapy Drugs for Cancer Revenue by Manufacturer (2021-2026)

3.3 Global Radioligand Therapy Drugs for Cancer Average Price by Manufacturer (2021-2026)

3.4 Market Share Analysis (2025)

3.4.1 Producer Shipments of Radioligand Therapy Drugs for Cancer by Manufacturer Revenue (\$MM) and Market Share (%): 2025

3.4.2 Top 3 Radioligand Therapy Drugs for Cancer Manufacturer Market Share in 2025

3.4.3 Top 6 Radioligand Therapy Drugs for Cancer Manufacturer Market Share in 2025

3.5 Radioligand Therapy Drugs for Cancer Market: Overall Company Footprint Analysis

3.5.1 Radioligand Therapy Drugs for Cancer Market: Region Footprint

3.5.2 Radioligand Therapy Drugs for Cancer Market: Company Product Type Footprint

3.5.3 Radioligand Therapy Drugs for Cancer Market: Company Product Application Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Radioligand Therapy Drugs for Cancer Market Size by Region

4.1.1 Global Radioligand Therapy Drugs for Cancer Sales Quantity by Region (2021-2032)

4.1.2 Global Radioligand Therapy Drugs for Cancer Consumption Value by Region (2021-2032)

4.1.3 Global Radioligand Therapy Drugs for Cancer Average Price by Region
(2021-2032)

4.2 North America Radioligand Therapy Drugs for Cancer Consumption Value
(2021-2032)

4.3 Europe Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032)

4.4 Asia-Pacific Radioligand Therapy Drugs for Cancer Consumption Value
(2021-2032)

4.5 South America Radioligand Therapy Drugs for Cancer Consumption Value
(2021-2032)

4.6 Middle East & Africa Radioligand Therapy Drugs for Cancer Consumption Value
(2021-2032)

5 MARKET SEGMENT BY TYPE

5.1 Global Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2021-2032)

5.2 Global Radioligand Therapy Drugs for Cancer Consumption Value by Type
(2021-2032)

5.3 Global Radioligand Therapy Drugs for Cancer Average Price by Type (2021-2032)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Radioligand Therapy Drugs for Cancer Sales Quantity by Application
(2021-2032)

6.2 Global Radioligand Therapy Drugs for Cancer Consumption Value by Application
(2021-2032)

6.3 Global Radioligand Therapy Drugs for Cancer Average Price by Application
(2021-2032)

7 NORTH AMERICA

7.1 North America Radioligand Therapy Drugs for Cancer Sales Quantity by Type
(2021-2032)

7.2 North America Radioligand Therapy Drugs for Cancer Sales Quantity by Application
(2021-2032)

7.3 North America Radioligand Therapy Drugs for Cancer Market Size by Country

7.3.1 North America Radioligand Therapy Drugs for Cancer Sales Quantity by Country
(2021-2032)

7.3.2 North America Radioligand Therapy Drugs for Cancer Consumption Value by
Country (2021-2032)

- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 EUROPE

- 8.1 Europe Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2021-2032)
- 8.2 Europe Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2021-2032)
- 8.3 Europe Radioligand Therapy Drugs for Cancer Market Size by Country
 - 8.3.1 Europe Radioligand Therapy Drugs for Cancer Sales Quantity by Country (2021-2032)
 - 8.3.2 Europe Radioligand Therapy Drugs for Cancer Consumption Value by Country (2021-2032)
 - 8.3.3 Germany Market Size and Forecast (2021-2032)
 - 8.3.4 France Market Size and Forecast (2021-2032)
 - 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
 - 8.3.6 Russia Market Size and Forecast (2021-2032)
 - 8.3.7 Italy Market Size and Forecast (2021-2032)

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Radioligand Therapy Drugs for Cancer Market Size by Region
 - 9.3.1 Asia-Pacific Radioligand Therapy Drugs for Cancer Sales Quantity by Region (2021-2032)
 - 9.3.2 Asia-Pacific Radioligand Therapy Drugs for Cancer Consumption Value by Region (2021-2032)
 - 9.3.3 China Market Size and Forecast (2021-2032)
 - 9.3.4 Japan Market Size and Forecast (2021-2032)
 - 9.3.5 South Korea Market Size and Forecast (2021-2032)
 - 9.3.6 India Market Size and Forecast (2021-2032)
 - 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
 - 9.3.8 Australia Market Size and Forecast (2021-2032)

10 SOUTH AMERICA

10.1 South America Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2021-2032)

10.2 South America Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2021-2032)

10.3 South America Radioligand Therapy Drugs for Cancer Market Size by Country

10.3.1 South America Radioligand Therapy Drugs for Cancer Sales Quantity by Country (2021-2032)

10.3.2 South America Radioligand Therapy Drugs for Cancer Consumption Value by Country (2021-2032)

10.3.3 Brazil Market Size and Forecast (2021-2032)

10.3.4 Argentina Market Size and Forecast (2021-2032)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2021-2032)

11.2 Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2021-2032)

11.3 Middle East & Africa Radioligand Therapy Drugs for Cancer Market Size by Country

11.3.1 Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Quantity by Country (2021-2032)

11.3.2 Middle East & Africa Radioligand Therapy Drugs for Cancer Consumption Value by Country (2021-2032)

11.3.3 Turkey Market Size and Forecast (2021-2032)

11.3.4 Egypt Market Size and Forecast (2021-2032)

11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)

11.3.6 South Africa Market Size and Forecast (2021-2032)

12 MARKET DYNAMICS

12.1 Radioligand Therapy Drugs for Cancer Market Drivers

12.2 Radioligand Therapy Drugs for Cancer Market Restraints

12.3 Radioligand Therapy Drugs for Cancer Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Radioligand Therapy Drugs for Cancer and Key Manufacturers

13.2 Manufacturing Costs Percentage of Radioligand Therapy Drugs for Cancer

13.3 Radioligand Therapy Drugs for Cancer Production Process

13.4 Industry Value Chain Analysis

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Radioligand Therapy Drugs for Cancer Typical Distributors

14.3 Radioligand Therapy Drugs for Cancer Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Radioligand Therapy Drugs for Cancer Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Radioligand Therapy Drugs for Cancer Consumption Value by Targeted Ligands, (USD Million), 2021 & 2025 & 2032

Table 3. Global Radioligand Therapy Drugs for Cancer Consumption Value by Radionuclides, (USD Million), 2021 & 2025 & 2032

Table 4. Global Radioligand Therapy Drugs for Cancer Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 5. Novartis Basic Information, Manufacturing Base and Competitors

Table 6. Novartis Major Business

Table 7. Novartis Radioligand Therapy Drugs for Cancer Product and Services

Table 8. Novartis Radioligand Therapy Drugs for Cancer Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 9. Novartis Recent Developments/Updates

Table 10. Bayer Basic Information, Manufacturing Base and Competitors

Table 11. Bayer Major Business

Table 12. Bayer Radioligand Therapy Drugs for Cancer Product and Services

Table 13. Bayer Radioligand Therapy Drugs for Cancer Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 14. Bayer Recent Developments/Updates

Table 15. Progenics (Lantheus) Basic Information, Manufacturing Base and Competitors

Table 16. Progenics (Lantheus) Major Business

Table 17. Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Product and Services

Table 18. Progenics (Lantheus) Radioligand Therapy Drugs for Cancer Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 19. Progenics (Lantheus) Recent Developments/Updates

Table 20. Acrotech Biopharma Inc Basic Information, Manufacturing Base and Competitors

Table 21. Acrotech Biopharma Inc Major Business

Table 22. Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Product and

Services

Table 23. Acrotech Biopharma Inc Radioligand Therapy Drugs for Cancer Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 24. Acrotech Biopharma Inc Recent Developments/Updates

Table 25. BMS Basic Information, Manufacturing Base and Competitors

Table 26. BMS Major Business

Table 27. BMS Radioligand Therapy Drugs for Cancer Product and Services

Table 28. BMS Radioligand Therapy Drugs for Cancer Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 29. BMS Recent Developments/Updates

Table 30. AstraZeneca Basic Information, Manufacturing Base and Competitors

Table 31. AstraZeneca Major Business

Table 32. AstraZeneca Radioligand Therapy Drugs for Cancer Product and Services

Table 33. AstraZeneca Radioligand Therapy Drugs for Cancer Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 34. AstraZeneca Recent Developments/Updates

Table 35. Eli Lilly Basic Information, Manufacturing Base and Competitors

Table 36. Eli Lilly Major Business

Table 37. Eli Lilly Radioligand Therapy Drugs for Cancer Product and Services

Table 38. Eli Lilly Radioligand Therapy Drugs for Cancer Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 39. Eli Lilly Recent Developments/Updates

Table 40. Convergent Therapeutics Basic Information, Manufacturing Base and Competitors

Table 41. Convergent Therapeutics Major Business

Table 42. Convergent Therapeutics Radioligand Therapy Drugs for Cancer Product and Services

Table 43. Convergent Therapeutics Radioligand Therapy Drugs for Cancer Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 44. Convergent Therapeutics Recent Developments/Updates

Table 45. Grand Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 46. Grand Pharmaceutical Major Business

Table 47. Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Product and

Services

Table 48. Grand Pharmaceutical Radioligand Therapy Drugs for Cancer Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 49. Grand Pharmaceutical Recent Developments/Updates

Table 50. Bivision Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 51. Bivision Pharmaceuticals Major Business

Table 52. Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Product and Services

Table 53. Bivision Pharmaceuticals Radioligand Therapy Drugs for Cancer Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 54. Bivision Pharmaceuticals Recent Developments/Updates

Table 55. Jiangsu Hengrui Basic Information, Manufacturing Base and Competitors

Table 56. Jiangsu Hengrui Major Business

Table 57. Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Product and Services

Table 58. Jiangsu Hengrui Radioligand Therapy Drugs for Cancer Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 59. Jiangsu Hengrui Recent Developments/Updates

Table 60. Global Radioligand Therapy Drugs for Cancer Sales Quantity by Manufacturer (2021-2026) & (K Units)

Table 61. Global Radioligand Therapy Drugs for Cancer Revenue by Manufacturer (2021-2026) & (USD Million)

Table 62. Global Radioligand Therapy Drugs for Cancer Average Price by Manufacturer (2021-2026) & (US\$/Unit)

Table 63. Market Position of Manufacturers in Radioligand Therapy Drugs for Cancer, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 64. Head Office and Radioligand Therapy Drugs for Cancer Production Site of Key Manufacturer

Table 65. Radioligand Therapy Drugs for Cancer Market: Company Product Type Footprint

Table 66. Radioligand Therapy Drugs for Cancer Market: Company Product Application Footprint

Table 67. Radioligand Therapy Drugs for Cancer New Market Entrants and Barriers to Market Entry

Table 68. Radioligand Therapy Drugs for Cancer Mergers, Acquisition, Agreements, and Collaborations

Table 69. Global Radioligand Therapy Drugs for Cancer Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR

Table 70. Global Radioligand Therapy Drugs for Cancer Sales Quantity by Region (2021-2026) & (K Units)

Table 71. Global Radioligand Therapy Drugs for Cancer Sales Quantity by Region (2027-2032) & (K Units)

Table 72. Global Radioligand Therapy Drugs for Cancer Consumption Value by Region (2021-2026) & (USD Million)

Table 73. Global Radioligand Therapy Drugs for Cancer Consumption Value by Region (2027-2032) & (USD Million)

Table 74. Global Radioligand Therapy Drugs for Cancer Average Price by Region (2021-2026) & (US\$/Unit)

Table 75. Global Radioligand Therapy Drugs for Cancer Average Price by Region (2027-2032) & (US\$/Unit)

Table 76. Global Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2021-2026) & (K Units)

Table 77. Global Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2027-2032) & (K Units)

Table 78. Global Radioligand Therapy Drugs for Cancer Consumption Value by Type (2021-2026) & (USD Million)

Table 79. Global Radioligand Therapy Drugs for Cancer Consumption Value by Type (2027-2032) & (USD Million)

Table 80. Global Radioligand Therapy Drugs for Cancer Average Price by Type (2021-2026) & (US\$/Unit)

Table 81. Global Radioligand Therapy Drugs for Cancer Average Price by Type (2027-2032) & (US\$/Unit)

Table 82. Global Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2021-2026) & (K Units)

Table 83. Global Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2027-2032) & (K Units)

Table 84. Global Radioligand Therapy Drugs for Cancer Consumption Value by Application (2021-2026) & (USD Million)

Table 85. Global Radioligand Therapy Drugs for Cancer Consumption Value by Application (2027-2032) & (USD Million)

Table 86. Global Radioligand Therapy Drugs for Cancer Average Price by Application (2021-2026) & (US\$/Unit)

Table 87. Global Radioligand Therapy Drugs for Cancer Average Price by Application (2027-2032) & (US\$/Unit)

Table 88. North America Radioligand Therapy Drugs for Cancer Sales Quantity by Type

(2021-2026) & (K Units)

Table 89. North America Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2027-2032) & (K Units)

Table 90. North America Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2021-2026) & (K Units)

Table 91. North America Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2027-2032) & (K Units)

Table 92. North America Radioligand Therapy Drugs for Cancer Sales Quantity by Country (2021-2026) & (K Units)

Table 93. North America Radioligand Therapy Drugs for Cancer Sales Quantity by Country (2027-2032) & (K Units)

Table 94. North America Radioligand Therapy Drugs for Cancer Consumption Value by Country (2021-2026) & (USD Million)

Table 95. North America Radioligand Therapy Drugs for Cancer Consumption Value by Country (2027-2032) & (USD Million)

Table 96. Europe Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2021-2026) & (K Units)

Table 97. Europe Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2027-2032) & (K Units)

Table 98. Europe Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2021-2026) & (K Units)

Table 99. Europe Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2027-2032) & (K Units)

Table 100. Europe Radioligand Therapy Drugs for Cancer Sales Quantity by Country (2021-2026) & (K Units)

Table 101. Europe Radioligand Therapy Drugs for Cancer Sales Quantity by Country (2027-2032) & (K Units)

Table 102. Europe Radioligand Therapy Drugs for Cancer Consumption Value by Country (2021-2026) & (USD Million)

Table 103. Europe Radioligand Therapy Drugs for Cancer Consumption Value by Country (2027-2032) & (USD Million)

Table 104. Asia-Pacific Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2021-2026) & (K Units)

Table 105. Asia-Pacific Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2027-2032) & (K Units)

Table 106. Asia-Pacific Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2021-2026) & (K Units)

Table 107. Asia-Pacific Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2027-2032) & (K Units)

Table 108. Asia-Pacific Radioligand Therapy Drugs for Cancer Sales Quantity by Region (2021-2026) & (K Units)

Table 109. Asia-Pacific Radioligand Therapy Drugs for Cancer Sales Quantity by Region (2027-2032) & (K Units)

Table 110. Asia-Pacific Radioligand Therapy Drugs for Cancer Consumption Value by Region (2021-2026) & (USD Million)

Table 111. Asia-Pacific Radioligand Therapy Drugs for Cancer Consumption Value by Region (2027-2032) & (USD Million)

Table 112. South America Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2021-2026) & (K Units)

Table 113. South America Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2027-2032) & (K Units)

Table 114. South America Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2021-2026) & (K Units)

Table 115. South America Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2027-2032) & (K Units)

Table 116. South America Radioligand Therapy Drugs for Cancer Sales Quantity by Country (2021-2026) & (K Units)

Table 117. South America Radioligand Therapy Drugs for Cancer Sales Quantity by Country (2027-2032) & (K Units)

Table 118. South America Radioligand Therapy Drugs for Cancer Consumption Value by Country (2021-2026) & (USD Million)

Table 119. South America Radioligand Therapy Drugs for Cancer Consumption Value by Country (2027-2032) & (USD Million)

Table 120. Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2021-2026) & (K Units)

Table 121. Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Quantity by Type (2027-2032) & (K Units)

Table 122. Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2021-2026) & (K Units)

Table 123. Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Quantity by Application (2027-2032) & (K Units)

Table 124. Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Quantity by Country (2021-2026) & (K Units)

Table 125. Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Quantity by Country (2027-2032) & (K Units)

Table 126. Middle East & Africa Radioligand Therapy Drugs for Cancer Consumption Value by Country (2021-2026) & (USD Million)

Table 127. Middle East & Africa Radioligand Therapy Drugs for Cancer Consumption

Value by Country (2027-2032) & (USD Million)

Table 128. Radioligand Therapy Drugs for Cancer Raw Material

Table 129. Key Manufacturers of Radioligand Therapy Drugs for Cancer Raw Materials

Table 130. Radioligand Therapy Drugs for Cancer Typical Distributors

Table 131. Radioligand Therapy Drugs for Cancer Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Radioligand Therapy Drugs for Cancer Picture
- Figure 2. Global Radioligand Therapy Drugs for Cancer Revenue by Type, (USD Million), 2021 & 2025 & 2032
- Figure 3. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Type in 2025
- Figure 4. Lutetium 177 Examples
- Figure 5. Radium 223 Examples
- Figure 6. Actinium 225 Examples
- Figure 7. Others Examples
- Figure 8. Global Radioligand Therapy Drugs for Cancer Revenue by Targeted Ligands, (USD Million), 2021 & 2025 & 2032
- Figure 9. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Targeted Ligands in 2025
- Figure 10. by Peptides Examples
- Figure 11. Small Molecules Examples
- Figure 12. Antibodies Examples
- Figure 13. Others Examples
- Figure 14. Global Radioligand Therapy Drugs for Cancer Revenue by Radionuclides, (USD Million), 2021 & 2025 & 2032
- Figure 15. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Radionuclides in 2025
- Figure 16. α -emitters Examples
- Figure 17. β -emitters Examples
- Figure 18. Others Examples
- Figure 19. Global Radioligand Therapy Drugs for Cancer Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
- Figure 20. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Application in 2025
- Figure 21. Prostate Cancer Examples
- Figure 22. Liver Cancer Examples
- Figure 23. Breast Cancer Examples
- Figure 24. Lung Cancer Examples
- Figure 25. Others Examples
- Figure 26. Global Radioligand Therapy Drugs for Cancer Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 27. Global Radioligand Therapy Drugs for Cancer Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 28. Global Radioligand Therapy Drugs for Cancer Sales Quantity (2021-2032) & (K Units)

Figure 29. Global Radioligand Therapy Drugs for Cancer Price (2021-2032) & (US\$/Unit)

Figure 30. Global Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Manufacturer in 2025

Figure 31. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by Manufacturer in 2025

Figure 32. Producer Shipments of Radioligand Therapy Drugs for Cancer by Manufacturer Sales (\$MM) and Market Share (%): 2025

Figure 33. Top 3 Radioligand Therapy Drugs for Cancer Manufacturer (Revenue) Market Share in 2025

Figure 34. Top 6 Radioligand Therapy Drugs for Cancer Manufacturer (Revenue) Market Share in 2025

Figure 35. Global Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Region (2021-2032)

Figure 36. Global Radioligand Therapy Drugs for Cancer Consumption Value Market Share by Region (2021-2032)

Figure 37. North America Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 38. Europe Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 39. Asia-Pacific Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 40. South America Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 41. Middle East & Africa Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 42. Global Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Type (2021-2032)

Figure 43. Global Radioligand Therapy Drugs for Cancer Consumption Value Market Share by Type (2021-2032)

Figure 44. Global Radioligand Therapy Drugs for Cancer Average Price by Type (2021-2032) & (US\$/Unit)

Figure 45. Global Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Application (2021-2032)

Figure 46. Global Radioligand Therapy Drugs for Cancer Revenue Market Share by

Application (2021-2032)

Figure 47. Global Radioligand Therapy Drugs for Cancer Average Price by Application (2021-2032) & (US\$/Unit)

Figure 48. North America Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Type (2021-2032)

Figure 49. North America Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Application (2021-2032)

Figure 50. North America Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Country (2021-2032)

Figure 51. North America Radioligand Therapy Drugs for Cancer Consumption Value Market Share by Country (2021-2032)

Figure 52. United States Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 53. Canada Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 54. Mexico Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 55. Europe Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Type (2021-2032)

Figure 56. Europe Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Application (2021-2032)

Figure 57. Europe Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Country (2021-2032)

Figure 58. Europe Radioligand Therapy Drugs for Cancer Consumption Value Market Share by Country (2021-2032)

Figure 59. Germany Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 60. France Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 61. United Kingdom Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 62. Russia Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 63. Italy Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 64. Asia-Pacific Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Type (2021-2032)

Figure 65. Asia-Pacific Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Application (2021-2032)

Figure 66. Asia-Pacific Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Region (2021-2032)

Figure 67. Asia-Pacific Radioligand Therapy Drugs for Cancer Consumption Value Market Share by Region (2021-2032)

Figure 68. China Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 69. Japan Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 70. South Korea Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 71. India Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 72. Southeast Asia Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 73. Australia Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 74. South America Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Type (2021-2032)

Figure 75. South America Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Application (2021-2032)

Figure 76. South America Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Country (2021-2032)

Figure 77. South America Radioligand Therapy Drugs for Cancer Consumption Value Market Share by Country (2021-2032)

Figure 78. Brazil Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 79. Argentina Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 80. Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Type (2021-2032)

Figure 81. Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Application (2021-2032)

Figure 82. Middle East & Africa Radioligand Therapy Drugs for Cancer Sales Quantity Market Share by Country (2021-2032)

Figure 83. Middle East & Africa Radioligand Therapy Drugs for Cancer Consumption Value Market Share by Country (2021-2032)

Figure 84. Turkey Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 85. Egypt Radioligand Therapy Drugs for Cancer Consumption Value

(2021-2032) & (USD Million)

Figure 86. Saudi Arabia Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 87. South Africa Radioligand Therapy Drugs for Cancer Consumption Value (2021-2032) & (USD Million)

Figure 88. Radioligand Therapy Drugs for Cancer Market Drivers

Figure 89. Radioligand Therapy Drugs for Cancer Market Restraints

Figure 90. Radioligand Therapy Drugs for Cancer Market Trends

Figure 91. Porters Five Forces Analysis

Figure 92. Manufacturing Cost Structure Analysis of Radioligand Therapy Drugs for Cancer in 2025

Figure 93. Manufacturing Process Analysis of Radioligand Therapy Drugs for Cancer

Figure 94. Radioligand Therapy Drugs for Cancer Industrial Chain

Figure 95. Sales Channel: Direct to End-User vs Distributors

Figure 96. Direct Channel Pros & Cons

Figure 97. Indirect Channel Pros & Cons

Figure 98. Methodology

Figure 99. Research Process and Data Source

I would like to order

Product name: Global Radioligand Therapy Drugs for Cancer Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/RC10CDAFDE1CEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RC10CDAFDE1CEN.html>